Skip to main content

Table 1 Basic characteristics of cohorts

From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality

  COVID-19 Pneumonia (n = 164) Non-COVID-19 Pneumonia (n = 23) COVID-19 Convalescent Healthy Controls
Disease severity Disease severity
mild (n = 75) moderate (n = 57) severe (n = 32) moderate (n = 14) severe (n = 9) n = 101 n = 15
Gender
 Male 32 (42.7%) 31 (54.4%) 26 (81.3%) 10 (71.4%) 6 (66.7%) 48 (47.5%) 6 (40%)
 Female 43 (57.3%) 26 (45.6%) 6 (18.8%) 4 (28.6%) 3 (33.3%) 53 (52.5%) 9 (60%)
Age 57 (53–60) 57 (55–64) 69 (64–77) 53 (45–69) 68 (63–81) 60 (58–62) 36 (34–52)
BMI 25.8 (24.9–26.6) 26.9 (25.3–29.4) 26.0 (24.8–26.9) 24.9 (23.1–31.6) 28.4 (26.4–31.2) 26.4 (25.7–27.4) 22.5 (20.9–25.3)
A.Hypertension 20 (26.7%) 24 (42.1%) 23 (71.9%) 9 (64.3%) 7 (77.8%) 38 (37.6%) 0
CAD 3 (4.0%) 1 (1.8%) 10 (31.3%) 3 (50%)   4 (4%) 0
Diabetes mellitus 8 (10.7%) 7 (12.3%) 8 (25.0%) 2 (14.3%) 2 (22.2%) 11 (10.9%) 0
Hyperlipidemia 14 (18.7%) 11 (19.3%) 12 (37.5%) 4 (28.6%) 4 (44.4%) 16 (15.8%) 0
Renal insufficiency 1 (1.3%) 5 (8.8%) 8 (25.0%) 6 (42.9%) 5 (55.6%) 4 (4%) 0
COPD 1 (1.3%) 4 (7.0%) 4 (12.5%) 0 (0%) 1 (11.1%) 3 (3.0%) 0
Inflammatory diseases 11 (14.7%) 9 (15.8%) 2 (6.3%) 8 (57.1%) 1 (11.1%) 16 (15.8%) 0
Malignancy 10 (13.3%) 7 (12.3%) 5 (15.6%) 0 (0%) 1 (11.1%) 13 (12.9%) 0
ACE-I 6 (8.0%) 8 (14.0%) 12 (37.5%) 4 (28.6%) 3 (33.3%) 11 (10.9%) 0
ARB 7 (9.3%) 9 (15.8%) 6 (18.8%) 2 (14.3%) 3 (33.3%) 15 (14.9%) 0
Cortisone 2 (2.7%) 5 (8.8%) 6 (18.8%) 1 (7.1%) 2 (22.2%) 5 (5.0%) 0
Statins 10 (3.3%) 11 (19.3%) 11 (34.4%) 4 (28.6%) 3 (33.3%) 16 (15.8%) 0
ASS/Clopidogrel 7 (9.3%) 6 (10.5%) 9 (28.1%) 2 (14.3%) 3 (33.3%) 8 (7.9%) 0
PaO2:FiO2   363 (329–410) 138 (106–179) 349 (307–400) 137 (118–232)   
30-day mortality 0 (0%) 0 (0%) 11 (34.4%) 0 (0%) 3 (33.3%)   
Dialysis 0 (0%) 0 (0%) 8 (25.0%) 2 (14.3%) 3 (33.3%)   
Catecholamine 0 (0%) 0 (0%) 13 (40.6%) 0 (0%) 5 (55.6%)   
SOFA 0 1 (1–2) 5 (4–7) 2 (1–6) 6 (4–13)   
Maximum SOFA 0 1 (1–2) 10 (5–13) 2 (1–6) 11 (6–14)   
qSOFA
 0 75 (100%) 46 (80.7%) 9 (28.1%) 11 (78.6%) 1 (11.1%)   
 1 0 (0%) 9 (15.8%) 17(53.1%) 3(21.4%) 4 (44.4%)   
 2 0 (0%) 2 (3.5%) 6 (18.8%) 0 (0%) 2 (22.2%)   
 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (22.2%)   
  1. Table shows the demographic characteristics, medical history and clinical data of cohorts with COVID-19 pneumonia, non-COVID-19 pneumonia, 20 weeks convalescent and healthy controls. Nominal and ordinal variables are reported as count (percentage in cohort), continuous variables are reported as median (IQR). BMI body mass index, A. Hypertension arterial hypertension, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, SOFA sequential organ failure assessment score, qSOFA quick sequential organ failure assessment score
\